11/10/2021 7:13:44 AM
Taysha Gene Therapies Q3 Net Loss $51.2 Mln Or $1.35/shr Vs Loss Of $15.0 Mln Or $1.28/Shr Last Year
9/29/2021 7:07:33 AM
Taysha Gene Therapies Receives Orphan Drug Designation From EU For TSHA-101 For Infantile GM2 Gangliosidosis
9/29/2021 7:06:36 AM
Taysha Gets Orphan Drug Designation From European
Commission For TSHA-101 For Infantile GM2 Gangliosidosis
9/22/2021 7:10:28 AM
Taysha Gets Orphan Drug Designation From European Commission For TSHA-102 For Rett Syndrome
8/25/2021 7:05:46 AM
Taysha Gene Therapies Granted Orphan Drug Designation From European Commission For TSHA-105 For Epilepsy
8/16/2021 7:12:52 AM
Taysha Gene Therapies Q2 Net Loss $40.9 Mln Or $1.09/Shr Vs Loss Of $21.2 Mln Or $1.95/Shr Last Year
6/21/2021 7:23:48 AM
Taysha Gene Therapies Announces Publication Of Natural History Data For TSHA-120 In GAN In The Journal, Brain
5/13/2021 7:16:05 AM
Taysha Gene Therapies Names Mary Newman As Chief Development
Officer
5/11/2021 7:12:22 AM
Taysha Gene Therapies Q1 Net Loss $32.0 Mln Or $0.87/Shr Vs Loss Of $5.4 Mln Or $0.50/Shr Last Year
4/12/2021 7:19:35 AM
Taysha Gene Therapies Acquires Exclusive Worldwide
rights To Clinical-stage AAV9 Gene Therapy Program
3/9/2021 7:12:13 AM
Taysha Gene Therapies Announces Multi-year Collaboration To Advance Mini-gene Payloads For AAV Gene Therapies
3/3/2021 7:29:25 AM
Taysha Gene Therapies FY Net Loss $60.0 Mln Or $3.40/Shr Vs Loss Of $1.1 Mln Or $0.12/Shr Last Year
1/26/2021 8:31:40 AM
Taysha Gene Therapies Names Timothy Douros Chief Legal Officer And Corporate Secretary
1/4/2021 7:26:09 AM
Taysha Gene Therapies Collaborates With AllStripes On SURF1-Associated Leigh Syndrome Clinical Development
12/29/2020 7:03:46 AM
Taysha Gene Therapies Appoints Greg Gara As SVP Of Manufacturing
11/24/2020 7:21:45 AM
Taysha Gene Therapies Appoints Kathy Reape And Laura Sepp-Lorenzino To Board
10/14/2020 7:03:45 AM
Taysha Gets Rare Pediatric Disease Designation And Orphan
Drug Designation For TSHA-102 As Treatment For Rett Syndrome
10/6/2020 7:23:17 AM
Taysha Gene Therapies Partners With Invitae To Support Invitae's Detect LSDs And Behind Seizure Programs